Nasdaq Moves to Delist Healthcare Triangle After Bid Price Falls Below $1
HCTI is trading near its 52-week low of $0.65 (8.0% above the low) on light trading volume (0.2× avg).
Summary
Nasdaq has issued a Staff Delisting Determination against Healthcare Triangle for failing to maintain a $1.00 minimum bid price. The company is ineligible for a compliance period due to prior reverse splits and must appeal by October 8, 2026, to avoid suspension of trading on October 12, 2026.
Key Events · Legal and Risk Events · HCTI
-
Nasdaq Staff Delisting Determination
On October 1, 2026, Nasdaq notified Healthcare Triangle that its securities are subject to delisting for failing to maintain a $1.00 minimum closing bid price under Listing Rule 5550(a)(2).
-
Ineligible for Compliance Period
The company is not eligible for the standard 180-day compliance period because it effected a 1-for-249 reverse split on August 1, 2025, and a 1-for-60 reverse split on February 10, 2026, for a cumulative ratio of 1-for-14,940 over the prior two years.
-
Suspension Deadline October 12, 2026
Unless the company requests an appeal by October 8, 2026, trading will be suspended at the opening of business on October 12, 2026, and a Form 25-NSE will be filed to remove the securities from listing and registration on Nasdaq.
-
Company to Appeal to Hearings Panel
Healthcare Triangle intends to request a hearing before the Nasdaq Hearings Panel, which would stay the suspension and Form 25-NSE filing pending the Panel's decision and any additional extension period granted.
Analysis · HCTI · Technology
Nasdaq issued a Staff Delisting Determination on October 1, 2026, because HCTI's closing bid price fell below the $1.00 minimum required for continued listing on the Nasdaq Capital Market. The company is ineligible for the standard 180-day compliance period because it has effected reverse stock splits with a cumulative ratio of 1-for-14,940 over the prior two years — a 1-for-249 split in August 2025 and a 1-for-60 split in February 2026. Unless the company appeals by October 8, 2026, trading will be suspended on October 12, 2026, and a Form 25-NSE will be filed to remove the stock from Nasdaq. The company intends to request a hearing before the Nasdaq Hearings Panel, which would stay the suspension while the Panel reviews the case. This is a critical governance and liquidity event: delisting would force the stock to trade on the OTC market, reducing institutional access and likely increasing volatility. The company's plan to regain compliance may include yet another reverse stock split, which would further compress the share count and could accelerate the very price declines that triggered this notice.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 39.9% of the 323 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HCTI was trading at $0.70 on NASDAQ in the Technology sector, with a market capitalization of approximately $10.9M. The 52-week trading range was $0.65 to $204.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.